Bio International Convention

BIO-Europe caters to the needs of the entire value chain, startup and innovator educational programmes, industry trends and outlooks from KOLs, company pitches, professional partnering meetings as well as ample serendipitous networking opportunities are part of the ROI proven feature set.Over the last 29 years, BIO-Europe, year after year, has grown not just in size but most importantly in becoming Europe’s flagship partnering event. Its international reach makes it a one of a kind offering and the gateway to the global life science community. Attendees from all parts of the biotechnology value chain gather to efficiently identify, engage and form strategic relationships that drive their businesses successfully forward.

A drafting group tasked with ensuring uniformity of terminology throughout the text of the draft convention and harmonizing the versions in the official languages of the United Nations reviewed the text from September to November 2006.
• A person in a wheelchair might have difficulties being gainfully employed not because of her condition but because there are environmental barriers such as inaccessible buses or staircases in the workplace which obstruct his or her access.

The drafters of this Convention were clear that disability should be seen as the result of the interaction between a person and his or her environment. Disability is not something that resides in the individual as the result of some impairment. This convention recognizes that disability is an evolving concept and that legislation may adapt to reflect positive changes within society.
The convention calls for the “progressive realization” of most of its provisions, in line with the resources of individual countries. Some steps will require money and for countries where resources are scarce, it is hoped that international assistance—which has neglected the needs of persons with disabilities—will help.Throughout history, persons with disabilities have been viewed as individuals who require societal protection and evoke sympathy rather than respect. This convention is a major step toward changing the perception of disability and ensures that societies recognize that all people must be provided with the opportunities to live life to their fullest potential, whatever that may be.

The rights enumerated in the Universal Declaration of Human Rights, in a perfect world, would be enough to protect everyone. But in practice certain groups, such as women, children and refugees have fared far worse than other groups and international conventions are in place to protect and promote the human rights of these groups. Similarly, the 650 million people in the world living with disabilities—about 10 per cent of the world’s population—lack the opportunities of the mainstream population. They encounter a myriad of physical and social obstacles that:
While some countries have enacted comprehensive legislation in this regard, many have not. Because of discriminatory practices, persons with disabilities tend to live in the shadows and margins of society, and as a result their rights are overlooked. A universal, legally binding standard is needed to ensure that the rights of persons with disabilities are guaranteed everywhere. The negotiations of the Convention embodied the principle ‘nothing about us, without us’. The Convention was drafted by the Ad Hoc Committee on a Comprehensive and Integral International Convention on the Protection and Promotion of the Rights and Dignity of Persons with Disabilities (Ad Hoc Committee), which is a committee of the United Nations General Assembly. Its membership is open to all United Nations Member States and observers. During its first session, the Ad Hoc Committee decided that representatives from non-governmental organizations (NGOs) accredited to the Ad Hoc Committee could also participate in meetings and make statements in accordance with United Nations practice. Since then, the General Assembly has repeatedly urged that efforts be made to actively involve disability organizations in the work of the Ad Hoc Committee. Throughout the process organizations of persons with disabilities and other NGOs have been very active in providing comments and information from a disability perspective. • A child with an intellectual disability might have difficulties going to school due to the attitudes of teachers, school boards and possibly parents who are unable to adapt to students with different learning capacities.By ratifying a convention, and after the treaty comes into force, a country accepts its legal obligations under the treaty and will adopt implementing legislation.

Since its establishment, the Ad Hoc Committee held eighth sessions. At its first two sessions, in 2002 and 2003, the Committee considered the possibility of drafting an international instrument on the rights of persons with disabilities, and discussed the type of instrument and possible elements to be included. At its second session, the Ad Hoc Committee established a working group to prepare a draft text of a convention. The Working Group, composed of government and NGO representatives, met in January 2004 and drafted a text for negotiation. At its third, fourth, fifth, sixth, seventh and eighth sessions the Ad Hoc Committee continued its negotiations. The Convention text was finalized by the Ad Hoc Committee on 26 August 2006.
The purpose of the Convention is to promote, protect and ensure the full and equal enjoyment of all human rights by persons with disabilities. The articles of the Convention recognize all rights, civil, cultural, economic, political, and social. The United Nations promotes the notion that these rights cannot be separated, and thus the Convention addresses them as integrated aspects of the entire spectrum of individuals’ rights. These rights identify action-oriented policy interventions for States to adopt in order to actively bring legislative and judicial systems in line with the Convention.In most parts of the world there are deep and persistent negative stereotypes and prejudices against persons with certain conditions and differences. These attitudes themselves also shape who is considered to be a person with a disability in each society as well as have contributed to a negative image of persons with disabilities. The language used to refer to persons with disabilities has played a significant role in the persistence of negative stereotypes. Clearly, terms such as “crippled” or “mentally retarded” are derogative. Other terms such as “wheelchair-bound” or “disabled persons” emphasize the disability before the person.

The term persons with disabilities is used to apply to all persons with disabilities including those who have long-term physical, mental, intellectual or sensory impairments which, in interaction with various attitudinal and environmental barriers, hinders their full and effective participation in society on an equal basis with others. However, this minimum list of persons who may claim protection under the Convention does not exhaust the categories of the disabilities which fall within the it nor intend to undermine or stand in the way of wider definition of disabilities under national law (such as persons with short-term disabilities). It is also important to note that a person with disabilities may be regarded as a person with a disability in one society or setting, but not in another, depending on the role that the person is assumed to take in his or her community. The perception and reality of disability also depend on the technologies, assistance and services available, as well as on cultural considerations.
Charity Williams, former CEO of medical device startup Veritract and now partner at Cooley LLP, hosted a panel that drew together experts in biopharma AI to explain the current state of the market and explore where there are opportunities
for growth. The panelists, including Nawal Roy, CEO of Holmusk, and Bhaskar Dutta, head of Digital Health at Alexion Pharmaceuticals, and Kevin Heyries, CBO of Inceptive, shared insights, beginning with their views on where AI stood in the biopharma ecosystem today.The COVID-19 pandemic saw an enormous level of investment driven into the biopharma sector. Yet, in the post-pandemic period, the market has turned somewhat more south. With venture capital drying up and the bottom falling out of the biotech IPO market, the panel session titled ‘Navigating Partnering in a Down Market’ could not be timelier. Jay Parris, Venture Partner at Arch Venture Partners, Ken Drazen, CEO of Arsenal Biosciences, and Sophie Kornowski, CEO of Boston Pharmaceuticals, shared their insights on the best way to partner in this new economic reality, with moderator Kate Hillier of Cooley starting the conversation by asking the panelists where the challenges and opportunities lie today.

Companies with experience in data science, analytics, AI and ML models, and a track record in generating value from data that pharma companies have not been able to leverage previously. Roy offered an example of this data in discussing opportunities in advancing mental health therapies. “Within the mental health space, there is a huge amount of unstructured data beyond the structured data that is in the notes of the doctors,” he said. “This unstructured data was not necessarily part of the thinking when a company is doing patient phenotyping. We are probably one of the few companies that have been able to do that in a very meaningful fashion, and we have been doing it for the last eight years.”
The panelists highlighted how, for small companies, there is a new struggle to raise sufficient capital. As a result, both consolidation between struggling companies and non-traditional deals are becoming more common. However, expectations need to be set, as these deals are not likely to be flashy deals seen during an up market. As one panelist put it bluntly, “You’re just not going to get that flashy $100 million upfront deal.”Kornowski, though, suggested that small companies should be cautious about entering into deals that may ultimately cost more than they are worth. Instead, these companies may be better off monetizing their assets early-on, so they are well-positioned to be acquired later.

Finally, the panel turned their attention to the biopharma nonprofits and small, early-stage companies. While their general advice remained the same, they also urged these groups to be more flexible, remain realistic about the market they are raising capital in, and to be open to new ideas and collaborations. Smaller companies are usually more agile and have a capacity to make decisions faster than larger organizations in the biopharma ecosystem, leaving them perfectly positioned to meet their clinical, fundraising, and business goals.
Is AI delivering a revolution in biopharma development, is it an accelerator for global health care innovation, or is it another ‘next big thing’ that won’t deliver on its significant hype? For panelists discussing ‘The Art and Science of Applying AI in the Race to Protect Global Public Health’, there was plenty of optimism about the potential for AI to contribute to future therapies, as well as some caution around its unregulated or irresponsible application to biopharma development.Moving into the practicalities of partnering, the panelists noted the importance of relationships in the biopharma industry and noted how essential trust-building remains. When setting targets, they cautioned against relying too heavily on comparable deals, and instead, argued that internal assessments should be completed to determine what the company needs as well as what it wants. If the final deal value requested is backed by a strong due diligence process and if the cost of capital and the net present value (NPV) of the asset have both been assessed, you have something that can be justified in a negotiation. “It might be a high justifiable number, but you can stand your ground,” summarized Hillier. “If you come up with something that’s just a number out of the air and you’ve got nothing to back it up, then there probably is some loss of face.”

Artificial intelligence (AI), machine learning (ML), and advanced data science techniques have touched many industries in recent years, not least of which is biopharma. At the BIO International Convention, a strong and diverse Digital Health conference program that has focused on the role of these new technologies in advancing patient care, developing new therapies, and driving innovation but, in this panel, the focus was clearly on how this technology is impacting deals and partnering.
Collaboration and partnership in biopharma have become increasingly important in recent years. Top pharma companies are increasingly collaborating with smaller biotechs to fill their pipelines and generate innovations, some of which were impossible to imagine just a few years ago. GSK is typical of this approach, and on this panel, its Chief Scientific Officer, Tony Wood, joined his colleague and head of Business Development, Chris Sheldon, to highlight two partnerships that the company has established with Wave Life Sciences and ViiV Healthcare.The panelists also spoke to the challenges that biotechs faced in securing venture capital or other investments to drive their innovations forward. To attract investors and secure financing, biotech companies were encouraged to develop a compelling story, aim to partner early, consider alternative forms of financing, and build relationships with investors as well as with top pharma teams. Biotech leaders should keep their teams focused on execution, make sure they know their valuation, and be prepared to pivot their business if circumstances or clinical results demand it.Moorman explained how READI is using AI in their drug discovery projects. READI uses AI structural modeling programs like AlphaFold to extrapolate from the few structures of their targets that exist to understand how those structures are conserved. They also use in silico studies to optimize small molecules for action against all the targets they are pursuing. For his part, Verhoest explained that Pfizer also uses AI to design small molecules for a variety of disease indications. By finding patterns that are statistically significant in large data, they can make discoveries, predictions, and explorations that inform their drug development efforts.In the current down market, it is important to prioritize transformational assets and to be honest about the costs and potential of those assets when negotiating deals. They also highlight the importance of having a good alliance management team, building relationships with partners, and investing in personal interactions to build trust in business. “Once that deal is inked, it’s going to get bigger,” said Parris. “Having a good alliance management team, that’s talking to the other side and understands that we’re going to get 80% of the way there, and 20% we’ll figure out along the way.”

Panelists Nathaniel Moorman (Co-founder, READI), Patrick Verhoest (VP Medicine Design, Pfizer), and Hamza Ghadyali (Senior AI Specialist, SAS) joined moderator Peter Young (Pappas Capital), who kicked things off by asking what contributions AI and ML were making to drug development and healthcare today. For the panelists, these technologies are revolutionizing the accuracy and efficiency of small molecule drug design, enabling scientists to predict how molecules will interact with each other and with biological systems. Moorman argued that “the democratization of discovery” is another area wher
e AI and ML are making a significant impact, with companies and researchers already using these technologies for “enhanced screening and optimization.”
The biopharma ecosystem is diverse, encompassing everything from small laboratory teams through emerging biotechs, venture capital investors, healthcare advocacy groups, business advisory and expert consultants, and multinational pharmaceutical companies. Moving from a leadership role in one part of this ecosystem to a similar role in another part is not unusual, and usually it provides a chance for individuals to leverage their expertise and knowledge in new ways. For this panel, former biopharma executives turned venture capital investors Sheila Gujrathi (Ventyx), Maha Katabi (Sofinnova), Maria Fardis (Frazier Life Sciences), Mary Hedley (Eli Lilly), and Kimberly Ha (KKH Advisors) offered insights from their own journeys through the industry, and advice for biotech leaders in today’s down market.GSK has partnered with ViiV Healthcare on HIV, and Kim Smith, SVP Research and Development at ViiV, explained that it is this commitment to changing lives for the better that is at the foundation of their work together. “It’s such a great match for us to be working together,” she said. “We have a passion to change the patient treatment experience.”

Heyries argued that AI will become more integrated with drug development practices and will move up the food chain, with companies maintaining a competitive advantage if they can build unique platforms. Roy concurred, and added smart risk and smart capital will help push AI forward into spaces like mental health. For his part, Dutta believes that AI can help in better science, better operations, and better integration of a drug into a patient’s lifecycle but noted that the real transformational change is expected on the regulatory side, with more guidance and clarity anticipated.

In the field of HIV treatment and prevention, GSK has made significant progress. Its HIV business is 100% focused on delivering better medicine for people living with HIV, and it has been able to shift the paradigm from needing three drugs daily to now offering long-acting options that only need to be dosed every two months. Long-acting HIV treatment and prevention have been a game-changer for people living with HIV, reducing the stress and fear associated with taking daily medication and the risk of developing resistance to the medication. “We’ve been told by patients that taking a pill every day is a daily reminder of the fact they’re living with HIV,” explained Sheldon. “When we gave them long-acting treatments, they said that it was liberating, it was literally life changing, and we like that; it’s a good thing to change people’s lives in a positive way.”

What is the purpose of international conventions?
What is an international convention? An international convention or treaty is an agreement between different countries that is legally binding to the contracting States. Existing international conventions cover different areas, including trade, science, crime, disarmament, transport, and human rights.
Paul Bolno, CEO of Wave Life Sciences, and Wood explained how their collaboration on RNA medicines has brought value to both firms. The RNA editing platform developed by Wave Life is a unique technology that can be used to manipulate RNA molecules in a way that was never possible previously. Together, they have been working on developing new treatments for pulmonary and hepatic disease using RNA editing technology, creating new therapies that target specific diseases and medical conditions. By working together, these companies can create a more robust development pipeline and bring innovative treatments to market. This alignment between partners is important as, when it is lacking, collaboration can suffer. Effective communication and goal setting are essential to overcome the challenges of smaller companies partnering with multinational firms, and it is important to establish clear guidelines for how to handle potential areas of conflict early in the process of working together. With effective due diligence and trust-building, partnerships in biopharma can deliver the sorts of positive results that GSK, Wave Life, and ViiV have already demonstrated. On the business and dealmaking side, the three panelists talked about how AI will change the way the world looks at intellectual property (IP) and how to navigate the changes to IP. Specifically, there is going to be a shift from therapeutic efficacy being the key value-add of an asset to the data around a set of biomarkers, algorithms, and physical molecules being a source of enormous value. Yet, no matter where the value lies and what sort of deal might be in development, the panelists agreed that where a biopharma AI deal happens still matters a lot, and Europe is running behind the pack. “I don’t want to make a cliche statement,” Roy said, “but usually the deals happen faster in the U.S. versus Europe. That’s usually the case. Deals even happen faster in Asia than Europe.”Yet, such partnerships can pose several challenges that biotechs need to carefully consider and navigate. One of the main obstacles to cross-border partnerships is communication, as different countries have different norms and expectations when it comes to business communication, which can lead to misunderstandings and breakdowns in negotiations. As a result, it is important to establish clear communication channels and expectations from the start, to ensure smooth collaboration and win-win relationships. Another challenge is differences in due diligence processes which can complicate the evaluation of potential partners where companies or venture funds from different countries may not employ the same standards of diligence.

Data, of course, is critical for drug development, from identifying new targets to conducting clinical trials and gaining regulatory approval. However, the data landscape is complex and diverse, with data sources ranging from electronic health records to genomic data to social media. To address this challenge, pharmaceutical companies are increasingly partnering with other organizations to gain access to the data and expertise needed for drug development.
However, despite these efforts and early successes from top pharma companies like Pfizer and non-profit research labs like READI, there remain challenges. One of the biggest issues faced by AI and ML adopters is the industry’s siloed data, which makes research and innovation extremely difficult. To make progress, researchers and scientists need to break down those silos and collaborate better, sharing data in a way that still respects privacy and personal identifiable information (PII). Moreover, the need for high-quality data is another challenge. While there is already a large amount of healthcare data available, much of it is neither standardized nor readily accessible. Additionally, there are concerns about data security, as well as the potential for biases in the algorithms used to analyze the data.

Forming strong partnerships was a common refrain amongst the panelists for a variety of reasons. Partnerships, in particular, cross-border partnerships, provide companies with access to a wider pool of scientific talent, resources, and markets, which can lead to better products and services and help to establish a global network of contacts and collaborators. Transnational partnerships can help to bridge cultural and language barriers, providing companies with a better understanding of different markets and consumer preferences, which, in turn, can lead to better products and services. This can be critical for securing new business opportunities and staying ahead of the competition.Still, despite the challenges for AI and ML in healthcare, the panel remained rather optimistic. Ghadyali explained that “it’s very important that we leverage all the tools that we have, including AI and machine learning” in developing responses to global health challenges. AI and ML can aid in the deployment of drugs and vaccines, and algorithms can monitor electronic health record (EHR) data in real-time to identify patterns, and signal when something is different. The promise of AI is strong, even if the fruits of this innovation are still mostly blossoms on a larger tree.

Where is the UN Ocean Conference 2023?
The first UN water conference in a generation, the UN 2023 Water Conference, co-hosted by the Governments of Tajikistan and the Netherlands will be a watershed moment to mobilize Member States, the UN system and stakeholders alike to take action and bring successful solutions to a global scale.
This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw hearty participation from more than 18,000 biotechnology and pharma leaders. We have teamed up with our parent company, the leading biopharma partnering platform Inova, to deliver the top insights from the BIO International Convention.BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community.

Explore the floor of over 400+ exhibitors at BIO 2023. Celebrate day two with unique experiences brought to you by our incredible exhibitors and pavilions.
The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.

Where is bio 2024?
San Diego BIO 2024, the BIO International Convention, will take place 4-8 June 2024 in San Diego, CA, USA.
Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.BIO is going BIG for Monday’s Welcome Reception at Boston’s premier luxury music hall. Join us for food, drinks, and fun to kick off the week for BIO 2023.

Having served as the 22nd commissioner in 2016, Robert M. Califf, MD returned to lead the FDA as the 25th commissioner in 2022. He’s weathered a pandemic, attacks on the accelerated approval pathway, and an infant formula shortage. Califf has made fighting misinformation a top priority.
Innovative programming around the current and future state of biotech. Including areas like therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital.

What are the requirements of international conventions?
ConventionsIntroduction. … Adopting a convention. … Entry into force. … Signature, ratification, acceptance, approval and accession. … Signature. … Signature subject to ratification, acceptance or approval. … Accession. … Amendment.
From deal-making in uncertain times and lessons in the biotech trenches, get current insights and hear from leading industry leaders on this important topic.Jim will share his views on current market trends, and share key insights on how startups who are looking to raise financing from VCs should prepare for the pitch meeting.

Join the global power players in the biotech and pharma industry at the world’s most influential biotech meeting! Sign up for updates to receive everything you need to know about the BIO International Convention.
Chris will discuss how pharmaceutical companies and entrepreneurial biotech companies are advancing science for the benefit of patients and public health.Katie Couric, award-winning journalist, New York Times best-selling author, and longtime cancer advocate takes the Main Stage on Tuesday, June 6, where she will be interviewed by Rachel King, BIO CEO. Their discussion centers on Ms. Couric’s tireless pursuit to stand up for science and patients.

Which cell biology conferences in 2023?
The Cell Bio 2023 (ASCB | EMBO Meeting 2023) will take place 2-6 December 2023 in Boston, MA, USA.
Format will deliver four (4) days of BIO One-on-One Partnering for business development, networking events, along with expert-level programming content focused on the most pressing industry topics including COVID-19, Infectious Diseases, Oncology, Business Development, Financing Trends, Cell, and Gene Therapy, Digital Health, and more. There will be a variety of panels and presentations across all four (4) days,

Where is bio Europe 2023?
The 29th annual BIO-Europe will take place November 6–8, 2023 in Munich, Germany, and it will convene over 5,000 life science professionals representing more than 2,220 companies from over 60 countries. Attendees will take part in 27,000 one-to-one meetings over the course of the event.
Stand up for innovation. Stand up for truth. And stand up for science. It’s time to inspire, honor, and recognize the true value of the breakthrough work biotech performs for society. Today. And every day. Well into the future.We had over 10,000+ international and domestic companies attend BIO 2022 across the biotech industry. For the full list of participating companies, please click here. You may receive emails offering to sell BIO conference attendee lists. BIO does not sell attendee lists directly or through third parties. Please do not engage with anyone offering to sell BIO conference attendee lists. Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.Water is a dealmaker for the Sustainable Development Goals, and for the health and prosperity of people and planet. But our progress on water related goals and targets remains alarmingly off track, jeopardizing the entire sustainable development agenda.

The first UN water conference in a generation, the UN 2023 Water Conference, co-hosted by the Governments of Tajikistan and the Netherlands will be a watershed moment to mobilize Member States, the UN system and stakeholders alike to take action and bring successful solutions to a global scale. To catalyse action, the Conference is seeking voluntary commitments, galvanized by the Programme, to the Water Action Agenda.This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category.

We are excited to invite you to join and Flanders Investment & Trade at the Belgian Pavilion during the largest global event for the biotech & life sciences industry.

The BIO International Convention attracts thousands of biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.At the 2022 edition, BIO hosted +10,000 international and domestic industry leaders across the biotech industry. For the full list of participating companies, click here.

Leading biotech companies, top 25 pharma companies, top 20 CROs and CMOs, more than 300 academic institutions, government agencies and the leading consultants and service companies.Taking place in Boston, MA on 5-8 June 2023, BIO attracts thousands of biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.

Where is bio-Europe 2023?
The 29th annual BIO-Europe will take place November 6–8, 2023 in Munich, Germany, and it will convene over 5,000 life science professionals representing more than 2,220 companies from over 60 countries. Attendees will take part in 27,000 one-to-one meetings over the course of the event.
As is tradition, we invite you to join and Flanders Investment & Trade at the Belgian Pavilion during the largest global event for the biotech & life sciences industry. Stay tuned for more info!In 2023 BIO International Convention is standing up for science, for truth and innovation. It’s time to inspire, honor, and recognise the true value of the breakthrough work biotech performs for society. Today, and well into the wants to improve your user experience on this website. Therefore we make use of cookies. You are at any time able to change your cookie preferences via the cookie settings on the website.

As is tradition, we invite you to join and Flanders Investment & Trade at the Belgian Pavilion during the largest global event for the biotech & life sciences industry. Stay tuned for more info!
The BIO International Convention attracts 15,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy.RTI expert Don Bailey, PhD, spoke on a panel on modernizing newborn screening to keep up with transformative therapies and advances in diagnostics, treatment, and care. View more information about the panel below and learn more about RTI’s work around newborn screening.

The 2022 BIO International Convention convened global thought leaders addressing critical topics at the intersection of science, business, and policy from June 13-16, 2022 in San Diego, CA. The convention, which featured 100+ interactive sessions across 4 days, covered a variety of topics from therapeutic areas, patient advocacy, public policy, next-generation biotherapeutics, digital health, and COVID-19.

RNATICS will be attending the BIO International Convention 2023 in Boston, USA. Reach out if you want to learn more about our ongoing drug development activities and meet during the partnering sessions.The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Innovative programming around the current and future state of biotech. Including areas like therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital.

Currently an Exhibitor with BIO 2023? Review the exhibit floor, set up your directory listing, manage your Pavilion Sharee companies (if applicable), link to housing reservations, make payments, access the Exhibitor Service Toolkit, add Exhibitor Partnering opportunities, and much more.
Share in the festivities by providing food, drinks, and unique activities to showcase who you are, and help welcome delegates to the world’s largest biotechnology event.Whether you have already reserved your exhibition space or are looking to secure some for the 2023 BIO International Convention, you will find all information and resources to maximize your planning efforts and experience at the Convention. Join 14,000+ expected attendees, don’t miss out on the opportunity to showcase your company’s achievements, pipeline, and ability to network/collaborate with other leaders in the biotech industry.

Where is the Bio Conference 2023?
Boston, MA Where is the 2023 BIO International Convention taking place? BIO 2023 will be taking place at the Boston Convention and Exhibition Center (415 Summer St, Boston, MA 02210) in the Seaport District of Boston, MA. Cached
Your one-stop-shop for all things exhibition at BIO 2023 with our partner Freeman. Access your dashboard, shop products and services, view orders and invoices, and much more.Find unexpected business opportunities at Asia’s blockbuster biotech event. With leading biotechnology executives and investors attending from over 25 countries, this essential event is your ticket to engage with the biggest names in Taiwan’s burgeoning biotech sector. Reach out to for a discount code if you are a current member of BIO.

This preeminent global partnership event, produced by EBD Group and supported by BIO, unites the most innovative companies with leaders across the life science value chain. From informative presentations to partnering sessions and fireside chats, this event is your gateway to the global biopharma community. Join the new wave of life science pioneers and fuel the future of drug development. Reach out to for a discount code if you are a current member of BIO.
Build your network, stay on top of industry topics, advocate for issues critical to your interests, gain access to policymakers, and save money. Apply today to join an unparalleled network of BIO Members and to benefit from a number of resources and event discounts.Through education, collaboration and advocacy, BIO strives to drive a bio-revolution that cures patients, protects our climate, and nourishes humanity. Receive timely event updates, exclusive content, partnering and programming announcements, and more.The world’s ultimate biotech event is not to be missed! With over 14,000 attendees from every corner of the industry and the globe, this event is your chance to make invaluable connections with biotech and pharma professionals, get inspired by global thought leaders, and increase your company’s visibility on an international scale. Celebrate how science continues to transform our world with four exciting days of networking, programming, and partnering opportunities that will shape our industry’s future.

What are the three types of convention?
Different types of conventions include form conventions, story conventions and genre conventions.
The EBD Group and BIO bring you the largest gathering of biopharma executives in Europe. This must-attend event attracts leading dealmakers from biotech, pharma, and finance along with the most exciting emerging companies. With thousands of industry leaders in attendance, there are endless opportunities to form vital new partnerships. Reach out to for a discount code if you are a current member of BIO.

As the largest global non-profit biotechnology trade association representing startups to Fortune 500 companies, BIO is proud to host a portfolio of partnering conferences that not only unite and empower biotech innovators and their ecosystem to improve lives, but also offer a broad and unbiased venue to seek investment and BD&L opportunities. Review our comprehensive list of events below.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables, and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings. Maximize your investor outreach and business development activities during JPM week with BIO One-on-One Partnering™. Find your next potential partner among the many users of our popular system, regardless of what events you’re attending during JPM week. An invite-only event for top patient advocacy organizations, academia, regulators, and the biotechnology industry. Attendees share information on the development of innovative therapies, examine timely policy issues, discuss best practices, and explore ways to improve the lives of patients.

With IP facing challenges like never before, this event is the perfect opportunity to come together to support innovation and protect R&D. Experience timely, relevant educational sessions on issues affecting biotech IP. The conference also features informal networking events designed to promote discussion and foster industry relationships, and learn practical tips.Mid-day Wednesday, attendees took a break over coffee and snacks for an Equity and Inclusion Reception, where a variety of partners across the biotech diversity and inclusion ecosystem got the chance to network and talk about how we can advance DEI in the industry and healthcare as a whole.

What is the Bio International Convention?
The BIO International Convention attracts 15,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.
The Biotechnology Innovation Organization (BIO) International Convention is so much more than policy updates and panel sessions. The 2023 event, which returned to Boston in June, featured a number of networking events, receptions, workshops, and even late-night parties to help continue the conversations beyond the podiums.The U.S. Department of Agriculture (USDA) announced the historic approval of the sale of chicken meat made from cultivated cells, which could provide a …… The 2023 BIO International Convention convened attendees for more than 57,000 partnering meetings—a new record. We can’t wait to see what innovations come from these meetings! On Tuesday, June 6, a busy day of networking closed with a reception on the convention show floor, where attendees got the chance to mix and mingle while checking out the exhibitors’ booths.The convention began with a bang on Monday, June 5, when hundreds of attendees enjoyed food, drinks, dancing, and fun at Big Night Live, a luxury live music venue in Boston’s West End.

Getting people talking! 57,000 partnering meetings happening at #BIO2023 in #Boston this week attracting companies from all over the world & all parts of the industry. also brought together biotech communicators for a workshop sponsored by Uncapped Communications and featuring Axios Co-Founder Mike Allen and BIO communicators (including the editors of Good Day BIO and Bio.News). Attendees reconvened later in the evening with a communicators’ happy hour sponsored by Amgen—and a few then headed upstairs to dance the night away at the OUTbio Pride Month party co-sponsored by BIO, Blueprint Medicines, Goodwin, Sanofi, and Vertex Pharmaceuticals. Wednesday was almost everyone’s busiest day—and the fun didn’t stop on the show floor. The evening reception on June 7 at MGM Music Hall at Fenway featured a live performance by singer and songwriter Andy Grammer, perhaps best known for the 2010 song “Keep Your Head Up” Bitte beachten Sie: Auf Grund der Corona-Situation hat der Bund die Zahl der bisherigen Teilnahmen für alle Aussteller „genullt”. Sie gelten also wieder als Erstteilnehmer bis zur vierten Beteiligung ab jetzt, auch wenn Sie schon viele Jahre Aussteller am Gemeinschaftsstand waren. Wie immer gibt es zwei Beteiligungsmöglichkeiten:

Durch die großzügige Förderung des BMWi ist es aber für die Aussteller des German Pavilion möglich, für nur EUR 350 € am Partnering teilzunehmen (gilt nicht für Vollkostenaussteller).
Die BIO International Convention wird 2022, wieder ausschließlich als Präsenzmesse stattfinden (Stand heute) und zwar vom 13. bis 16. Juni in San Diego, USA.